510(k) Report

510(k) · Cleared

Cleared

Xpert Xpress CoV-2/Flu/RSV plus

K250996510(k) SpecialCleared May 1, 202530-day reviewClass II21 CFR 866.3981

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Cepheid® · QOF Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents

Cleared on May 1, 2025 as substantially equivalent to K231481 (Cepheid®, 2023) after a 30-day review. Its family tree reaches back 2 generations to 2021.

Decided
May 1, 2025
Review
30 days
Class
Class II
Product code
QOF
Recalls
None
Predicates
1

Its longest line of descent runs back 2 generations to DEN200031 (2021). No later device cites it as a predicate yet.

  1. Root · 2 generations backDEN200031 BioFire Respiratory Panel 2.1 (RP2.1)Biofire Diagnostics, LLC · 2021
  2. 1 generation backK231481 Xpert Xpress CoV-2/Flu/RSV plusCepheid® · 2023
  3. This deviceK250996 Xpert Xpress CoV-2/Flu/RSV plusCepheid® · 2025
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2DEN200031BioFire Respiratory Panel 2.1 (RP2.1)Biofire Diagnostics, LLC2021—
−1K231481Xpert Xpress CoV-2/Flu/RSV plusCepheid®2023—
0 (this device)K250996Xpert Xpress CoV-2/Flu/RSV plusCepheid®2025—
FIG. 1 — Lineage of K250996, 2021–2025Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in QOF? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new QOF device

  1. #1 K241240 Panther Fusion SARS-CoV-2/Flu A/B/RSV Assayscore 17.0 · 2 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K231481Xpert Xpress CoV-2/Flu/RSV plus
Summary page 7
…Microbiology (83) Classification Advisory Panel Prescription Use Yes Predicate Device Xpert Xpress CoV-2/Flu/RSV plus (K231481) Assay: 510(k) Summary Page 3 of 9 === Page 8 =…
Cepheid®2023—

Also cleared against K231481: 1 other device →

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 4 years and passes through 2 companies; a new generation was cleared every 2.4 years on median.
  • None of the 2 ancestors has a recall.
  • 1 other device also cites its predicate K231481.

How does its category compare?

All QOF devices

QOF Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents: FDA decisions, review times, recalls and adverse event reports over 20 years. 2025, this device’s year, is highlighted.

FDA decisions per year · QOF

13in 2025

2021: 12023: 72024: 92025: 132026 (partial year): 8
2007high 13 (2025) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · QOF

178in 2025

2023: 238 days median2024: 147 days median2025: 178 days median2026 (partial year): 128 days median
2007high 238 (2023) · low 147 (2024)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · QOF

2so far in 2026, the most since 2007

2023: 12024: 12025: 12026 (partial year): 2
2007high 2 (2026) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · QOF

10in 2025

2023: 62024: 302025: 10
2007high 30 (2024) · low 0 (2007)2025

MAUDE reports naming product code QOF, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20140—00
20150—00
20160—00
20170—00
20180—00
20190—00
20200—00
20211—00
20220—00
2023723816
20249147130
202513178110
202681282—

What is it indicated for?

The Xpert Xpress CoV-2/Flu/RSV plus test, performed on the GeneXpert Dx and GeneXpert Infinity Systems, is an automated multiplexed real-time reverse transcriptase polymerase chain reaction (RT-PCR) test intended for use in the simultaneous in vitro qualitative detection and differentiation of severe acute respiratory syndrome coronavirus (SARS-CoV-2), influenza A, influenza B, and/or respiratory syncytial virus (RSV) viral RNA in nasopharyngeal swab and…

Read the full statement (251 words)

The Xpert Xpress CoV-2/Flu/RSV plus test, performed on the GeneXpert Dx and GeneXpert Infinity Systems, is an automated multiplexed real-time reverse transcriptase polymerase chain reaction (RT-PCR) test intended for use in the simultaneous in vitro qualitative detection and differentiation of severe acute respiratory syndrome coronavirus (SARS-CoV-2), influenza A, influenza B, and/or respiratory syncytial virus (RSV) viral RNA in nasopharyngeal swab and anterior nasal swab specimens collected from individuals with signs and symptoms of respiratory tract infection. Clinical signs and symptoms of respiratory tract infection due to SARS-CoV-2, influenza A, influenza B, and RSV can be similar.

The Xpert Xpress CoV-2/Flu/RSV plus test is intended for use in the differential detection of SARS-CoV-2, influenza A, influenza B and/or RSV RNA and aids in the diagnosis of COVID-19, influenza and/or RSV infections if used in conjunction with other clinical and epidemiological information, and laboratory findings. SARS-CoV-2, influenza A, influenza B, and RSV viral RNA are generally detectable in nasopharyngeal swab and anterior nasal swab specimens during the acute phase of infection.

Positive results are indicative of the presence of the identified virus, but do not rule out bacterial infection or co-infection with other pathogens not detected by the test. The agent (s) detected by the Xpert Xpress CoV-2/Flu/RSV plus test may not be the definite cause of the disease.

Negative results do not preclude SARS-CoV-2, influenza A, influenza B and/or RSV infection. The results of this test should not be used as the sole basis for diagnosis, treatment or other patient management decisions.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K250996: Xpert Xpress CoV-2/Flu/RSV plus.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 4, 2026. https://510kreport.com/device/K250996

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026